• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by The Oncology Institute Inc.

    6/24/25 7:40:20 PM ET
    $TOI
    Medical/Nursing Services
    Health Care
    Get the next $TOI alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Oncology Institute, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    68236X100

    (CUSIP Number)


    05/15/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    68236X100


    1Names of Reporting Persons

    FOG Ventures Investments, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  This Amendment No. 1 to Schedule 13G is filed to amend the Schedule 13G filed by the Reporting Persons named therein on November 24, 2021. This Amendment No. 1 constitutes an "exit filing" for the Reporting Persons.


    SCHEDULE 13G

    CUSIP No.
    68236X100


    1Names of Reporting Persons

    Daniel Murillo
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  Daniel Murillo is the sole managing member of FOG Venture Investments, LLC and has voting and dispositive control over any shares it holds .


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Oncology Institute, Inc.
    (b)Address of issuer's principal executive offices:

    18000 STUDEBAKER RD, SUITE 800, CERRITOS, CA, 90703
    Item 2. 
    (a)Name of person filing:

    FOG Venture Investments, LLC Daniel Murillo
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office for each of the Reporting Persons is: 3270 Firestone Blvd, Ste 740, South Gate, CA 90280
    (c)Citizenship:

    See Row 4 of each Reporting Person's cover page to this Schedule 13G.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    68236X100
    Item 4.Ownership
    (a)Amount beneficially owned:

    See Row 9 of each Reporting Person's cover page to this Schedule 13G.
    (b)Percent of class:

    See Row 11 of each Reporting Person's cover page to this Schedule 13G.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Row 5 of each Reporting Person's cover page to this Schedule 13G.

     (ii) Shared power to vote or to direct the vote:

    See Row 6 of each Reporting Person's cover page to this Schedule 13G.

     (iii) Sole power to dispose or to direct the disposition of:

    See Row 7 of each Reporting Person's cover page to this Schedule 13G.

     (iv) Shared power to dispose or to direct the disposition of:

    See Row 8 of each Reporting Person's cover page to this Schedule 13G.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    FOG Ventures Investments, LLC
     
    Signature:/s/ Daniel Murillo
    Name/Title:Daniel Murillo/Chief Executive Officer
    Date:06/24/2025
     
    Daniel Murillo
     
    Signature:/s/ Daniel Murillo
    Name/Title:Daniel Murillo
    Date:06/24/2025
    Get the next $TOI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TOI

    DatePrice TargetRatingAnalyst
    7/23/2025$8.00Outperform
    Noble Capital Markets
    7/16/2025$6.00Buy
    B. Riley Securities
    5/15/2025$7.00Buy
    BTIG Research
    2/26/2024$2.50Buy
    Jefferies
    9/14/2022$7.00Buy
    Guggenheim
    8/15/2022$10.00Buy
    Jefferies
    More analyst ratings

    $TOI
    SEC Filings

    View All

    SEC Form 424B5 filed by The Oncology Institute Inc.

    424B5 - Oncology Institute, Inc. (0001799191) (Filer)

    8/13/25 5:20:16 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    SEC Form 10-Q filed by The Oncology Institute Inc.

    10-Q - Oncology Institute, Inc. (0001799191) (Filer)

    8/13/25 5:12:48 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Oncology Institute, Inc. (0001799191) (Filer)

    8/13/25 4:21:58 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $TOI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Hively Brad bought $47,168 worth of shares (45,280 units at $1.04), increasing direct ownership by 7% to 712,033 units (SEC Form 4)

    4/A - Oncology Institute, Inc. (0001799191) (Issuer)

    4/28/25 7:20:14 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Chief Executive Officer Virnich Daniel bought $23,584 worth of shares (22,640 units at $1.04), increasing direct ownership by 3% to 724,363 units (SEC Form 4)

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    3/28/25 5:50:27 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Chief Medical Officer Podnos Yale bought $9,434 worth of shares (9,056 units at $1.04), increasing direct ownership by 13% to 79,049 units (SEC Form 4)

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    3/28/25 5:48:39 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $TOI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hively Brad sold $82,097 worth of shares (20,221 units at $4.06), decreasing direct ownership by 3% to 622,980 units (SEC Form 4)

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    8/21/25 3:13:31 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Director Barasch Richard A

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    8/14/25 3:49:53 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Director Barasch Richard A disposed of 287,756 shares (SEC Form 4)

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    7/28/25 9:08:48 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $TOI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Oncology Institute and Doctors Healthcare Plans Partner to Elevate Oncology Care Management in South Florida

    CERRITOS, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute of Hope and Innovation (NASDAQ:TOI), a national leader in value-based oncology care, is pleased to announce a strategic partnership with Doctors HealthCare Plans, a Medicare Advantage plan serving members across South Florida. The Oncology Institute will provide delegated utilization management services and clinical advisory support, helping Doctors HealthCare Plans ensure high-quality, cost-effective cancer care for their members. Under this partnership, The Oncology Institute will deliver comprehensive utilization management functions for oncology services, leveraging its robust clinical protocols, medical direct

    8/18/25 8:00:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Reports Second Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance

    CERRITOS, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended June 30, 2025. Daniel Virnich, CEO of TOI, commented, "We delivered another strong quarter with over 20% year-over-year revenue growth. This was driven by exceptional performance in our pharmacy business, which grew over 40% year-over-year, as well as the addition of over 50,000 new capitated lives to our value-based business. We are also in the process of expanding our partnership into new geographic regions of Florida with a major

    8/13/25 4:05:00 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Announces Changes to Board of Directors

    CERRITOS, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Richard Barasch will retire from his role as Chairman of the Board, effective August 12, 2025. Anne McGeorge, who currently serves as a Board Member and Chair of the Audit Committee, will succeed Barasch in the role. "We are thrilled to have Anne McGeorge serve as our next Chairman of the Board," said Daniel Virnich, MD, CEO of The Oncology Institute. "Having worked with Anne since she joined The Oncology Institute's board in 2021, I feel confident that she is the right person for the job. Her exten

    8/13/25 4:04:00 PM ET
    $DNTH
    $TOI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Nursing Services

    $TOI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Noble Capital Markets initiated coverage on The Oncology Institute with a new price target

    Noble Capital Markets initiated coverage of The Oncology Institute with a rating of Outperform and set a new price target of $8.00

    7/23/25 9:21:53 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    B. Riley Securities initiated coverage on The Oncology Institute with a new price target

    B. Riley Securities initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $6.00

    7/16/25 7:58:29 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    BTIG Research initiated coverage on The Oncology Institute with a new price target

    BTIG Research initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $7.00

    5/15/25 8:12:51 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $TOI
    Financials

    Live finance-specific insights

    View All

    The Oncology Institute Reports Second Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance

    CERRITOS, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended June 30, 2025. Daniel Virnich, CEO of TOI, commented, "We delivered another strong quarter with over 20% year-over-year revenue growth. This was driven by exceptional performance in our pharmacy business, which grew over 40% year-over-year, as well as the addition of over 50,000 new capitated lives to our value-based business. We are also in the process of expanding our partnership into new geographic regions of Florida with a major

    8/13/25 4:05:00 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Announces Second Quarter 2025 Earnings Release Date and Conference Call

    CERRITOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that the company will release its second quarter 2025 financial results after the market close on Wednesday, August 13, 2025, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call a

    7/24/25 4:05:00 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance

    CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended March 31, 2025. Recent Operational Highlights Retail Pharmacy and Dispensary set fill records, contributing $49.3 million revenue and over $9 million in gross profit in Q1. The Pharmacy and Dispensary segment grew over 20% in the first quarter of 2025 vs. prior yearFee-for-service growth of 9% in Q1 2025 over Q4 2024, highlighting the impact of our investments in referral relationship management and call center expansion.Strong start

    5/14/25 4:06:58 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $TOI
    Leadership Updates

    Live Leadership Updates

    View All

    The Oncology Institute Names Kristin England as Chief Administrative Officer

    CERRITOS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI"), one of the largest value-based oncology groups in the United States, announced today that Kristin England has joined the organization as Chief Administrative Officer (CAO), effective July 7, 2025. In this newly established role, England will oversee Enterprise Central Business Operations and Technology Strategy and Enablement across TOI's expanding national footprint. England brings over two decades of leadership experience in healthcare management and operations, most recently serving as a senior executive within McKesson's US Oncology Network. There, she led high-performing teams focus

    7/14/25 4:05:25 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention

    Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation. Now, cancer experts are alarmed over a "gut wrenching" plan from the U.S. government to cut nearly 40% of National Cancer Institute funding, even as the price of oncology treatments pushes new limits—raising urgent concerns about access and affordability. In this shifting landscape, investors are turning their attention to a new wave of biotechs and specialty care providers developing breakthrough therapies and smarter care mo

    7/8/25 10:25:00 AM ET
    $CELC
    $CTOR
    $EXEL
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    The Oncology Institute set to join the Russell 2000® and Russell 3000® Indexes

    CERRITOS, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI"), one of the largest value-based oncology groups in the United States, today announced that it will join the Russell 2000® and Russell 3000® after the 2025 Russell indexes annual reconstitution, effective after the US market closes on June 27, according to a preliminary list of additions posted on May 23. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or s

    6/3/25 8:00:06 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $TOI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by The Oncology Institute Inc.

    SC 13D/A - Oncology Institute, Inc. (0001799191) (Subject)

    8/20/24 8:20:55 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    SEC Form SC 13D/A filed by The Oncology Institute Inc. (Amendment)

    SC 13D/A - Oncology Institute, Inc. (0001799191) (Subject)

    1/2/24 5:06:50 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G/A filed by The Oncology Institute Inc. (Amendment)

    SC 13G/A - Oncology Institute, Inc. (0001799191) (Subject)

    7/10/23 10:20:11 AM ET
    $TOI
    Medical/Nursing Services
    Health Care